Ziritaxestat
Small molecule
Evidence outlook · program status
Discontinued (2021-02-10), on a safety finding
GLPG1690 (ziritaxestat) was the autotaxin inhibitor in the ISABELA Phase 3 programme for idiopathic pulmonary fibrosis. On 10 February 2021 Galapagos and Gilead halted both ISABELA studies (NCT03711162 and NCT03733444) after the Independent Data Monitoring Committee concluded that the benefit-risk profile of ziritaxestat no longer supported continuing them. The systemic sclerosis extension NOVESA-OLE (NCT03976648) was terminated with the same benefit-risk wording. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ISABELA2 NCT03733444 · Idiopathic Pulmonary Fibrosis ISABELA 2 was a randomized, double-blind, placebo-controlled Phase 3 trial of GLPG1690 (ziritaxestat) 600 mg or 200 mg added to standard care in 781 patients with idiopathic pulmonary fibrosis. The primary endpoint was the annual rate of FVC decline to week 52. The decline was almost identical in all three arms (600 mg +2.8 mL vs placebo, p=0.9123; 200 mg +1.7 mL, p=0.9456), so the primary was missed. Source: CT.gov posted results. Registry: NCT03733444 | 3 | Annual Rate of Decline in Forced Vital Capacity (FVC) up to Week 52 (Baseline up to week 52) 2021-03-30 | Annual rate of FVC decline to week 52: GLPG1690 600 mg -173.8 mL/yr, 200 mg -174.9 mL/yr, placebo -176.6 mL/yr; difference vs placebo +2.8 mL (95% CI -46.9 to 52.4), p=0.9123, and +1.7 mL (95% CI -47.4 to 50.8), p=0.9456 (CT.gov posted results). | not yet graded | link ↗ |
View 1 more trial
ISABELA1 NCT03711162 · Idiopathic Pulmonary Fibrosis ISABELA 1 was a randomized, double-blind, placebo-controlled Phase 3 trial of GLPG1690 (ziritaxestat) 600 mg or 200 mg added to standard care in 525 patients with idiopathic pulmonary fibrosis. The primary endpoint was the annual rate of FVC decline to week 52. Neither dose differed from placebo (600 mg +22.7 mL, p=0.5525; 200 mg -26.7 mL, p=0.4776), so the primary was missed. Source: CT.gov posted results. Registry: NCT03711162 | 3 | Annual Rate of Decline in FVC up to Week 52 (Baseline up to week 52) 2021-03-30 | Annual rate of FVC decline to week 52: GLPG1690 600 mg -124.6 mL/yr, 200 mg -173.9 mL/yr, placebo -147.3 mL/yr; difference vs placebo +22.7 mL (95% CI -52.3 to 97.6), p=0.5525, and -26.7 mL (95% CI -100.5 to 47.1), p=0.4776 (CT.gov posted results). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Idiopathic Pulmonary Fibrosis: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ziritaxestat: this drug | Discontinued | Small molecule | autotaxin (ENPP2) | not yet graded | No reviewed efficacy summary in this indication | |
| Nerandomilast (Jascayd) | Approved | Small molecule | PDE4B | Reliable signal | NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88) | |
| Nintedanib (Ofev) | Approved | Small molecule | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) | Partial signal | NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results). NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results). | |
| Pirfenidone (Esbriet) | Approved | Small molecule | Pyridone | Reliable signal | NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results). | |
| Treprostinil (Tyvaso DPI) | Approved(overall) | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 3 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-722 | Phase 1(overall) | Small molecule | LPAR1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.